GlassScriptPhysician profile
Sara M Strauss
NPI 1104119460
$576.17
in general payments reported to CMS, 2019-2025
11 companies · $52.66 in 2025
The $52.66 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.34 · 2020: $59.21 · 2021: $104 · 2022: $263 · 2023: $58.92 · 2025: $52.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $111.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $193.95 | 2020-2022 | |
| Boston Scientific Corporation | $141.98 | 2022 | |
| Sk Life Science, INC. | $44.44 | 2022-2023 | |
| Ucb, INC. | $39.97 | 2019-2023 | Briviact |
| Stryker Corporation | $37.22 | 2021-2022 | |
| Greenwich Biosciences, INC. | $26.55 | 2019 | |
| Medtronic, INC. | $22.16 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.47 | 2025 | Hyqvia |
| Lilly USA, LLC | $17.60 | 2025 | Kisunla |
| Astrazeneca Pharmaceuticals LP | $17.24 | 2023 | Andexxa |
| Neurelis, INC. | $16.59 | 2025 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Strauss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.